|View printer-friendly version|
Voyager Therapeutics to Present at Upcoming Investor Conferences in October 2019
Cantor Global Healthcare Conference, New York, NY
Wednesday, October 2, 2019
8:55 a.m. EDT
- Chardan 3rd Annual
Genetic Medicines Conference, New York, NY
Monday, October 7, 2019
2:30 p.m. EDT
Live-streaming webcasts of the presentations can be accessed through the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. The webcasts will be archived for 30 days after the live events conclude.
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager’s wholly-owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson’s disease, Huntington’s disease, a monogenic form of ALS called SOD1, Friedreich’s ataxia, Alzheimer’s disease, and other neurodegenerative diseases related to defective or excess aggregation of tau and alpha-synuclein proteins in the brain. Voyager has strategic collaborations with
Chief Financial Officer
Source: Voyager Therapeutics, Inc.